Swiss National Bank
TRDA icon

Swiss National Bank’s Entrada Therapeutics TRDA Stock Holding History

Swiss National Bank’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-32,800
Closed -$297K – 2396
2025
Q1 		$297K Hold
32,800
– – ﹤0.01% 2387
2024
Q4 		$567K Hold
32,800
– – ﹤0.01% 2385
2024
Q3 		$524K Hold
32,800
– – ﹤0.01% 2426
2024
Q2 		$467K Buy
32,800
+9,800
+43% +$139K ﹤0.01% 2427
2024
Q1 		$326K Hold
23,000
– – ﹤0.01% 2494
2023
Q4 		$347K Sell
23,000
-2,200
-9% -$32.6K ﹤0.01% 2514
2023
Q3 		$398K Hold
25,200
– – ﹤0.01% 2548
2023
Q2 		$382K Buy
25,200
+1,500
+6% +$20.7K ﹤0.01% 2578
2023
Q1 		$344K Sell
23,700
-2,800
-11% -$37.4K ﹤0.01% 2591
2022
Q4 		$358K Buy
+26,500
New +$465K ﹤0.01% 2630

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return

Swiss National Bank's TRDA Position: Q2 2025 in Review

Swiss National Bank sold out of Entrada Therapeutics (TRDA) in Q2 2025, closing a stake of 32,800 shares — an estimated $297K sold.

Swiss National Bank first reported a position in TRDA in Q4 2022 and held it in 10 quarters. The position peaked at $567K in Q4 2024. 107 funds tracked by Wall St. Rank hold TRDA as of Q2 2025.

  • Swiss National Bank reported no remaining Entrada Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Swiss National Bank sold 32,800 Entrada Therapeutics shares in Q2 2025, an estimated $297K.
  • Swiss National Bank first reported a position in Entrada Therapeutics in Q4 2022 and held it in 10 quarters.
  • Swiss National Bank's Entrada Therapeutics position peaked at $567K in Q4 2024.
  • 107 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2025.

Based on Swiss National Bank's 13F filing for Q2 2025, filed 12 Aug 2025.